» Articles » PMID: 28978711

Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex

Overview
Journal J Virol
Date 2017 Oct 6
PMID 28978711
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The trimeric envelope glycoprotein spike (Env) of HIV-1 is the target of vaccine development to elicit broadly neutralizing antibodies (bnAbs). Env trimer instability and heterogeneity in principle make subunit interfaces inconsistent targets for the immune response. Here, we investigate how functional stability of Env relates to neutralization sensitivity to V2 bnAbs and V3 crown antibodies that engage subunit interfaces upon binding to unliganded Env. Env heterogeneity was inferred when antibodies neutralized a mutant Env with a plateau of less than 100% neutralization. A statistically significant correlation was found between the stability of mutant Envs and the MPN of V2 bnAb, PG9, as well as an inverse correlation between stability of Env and neutralization by V3 crown antibody, 447-52D. A number of Env-stabilizing mutations and V2 bnAb-enhancing mutations were identified in Env, but they did not always overlap, indicating distinct requirements of functional stabilization versus antibody recognition. Blocking complex glycosylation of Env affected V2 bnAb recognition, as previously described, but also notably increased functional stability of Env. This study shows how instability and heterogeneity affect antibody sensitivity of HIV-1 Env, which is relevant to vaccine design involving its dynamic apex. The Env trimer is the only viral protein on the surface of HIV-1 and is the target of neutralizing antibodies that reduce viral infectivity. Quaternary epitopes at the apex of the spike are recognized by some of the most potent and broadly neutralizing antibodies to date. Being that their glycan-protein hybrid epitopes are at subunit interfaces, the resulting heterogeneity can lead to partial neutralization. Here, we screened for mutations in Env that allowed for complete neutralization by the bnAbs. We found that when mutations outside V2 increased V2 bnAb recognition, they often also increased Env stability-of-function and decreased binding by narrowly neutralizing antibodies to the V3 crown. Three mutations together increased neutralization by V2 bnAb and eliminated binding by V3 crown antibodies. These results may aid the design of immunogens that elicit antibodies to the trimer apex.

Citing Articles

Inducible cell lines producing replication-defective human immunodeficiency virus particles containing envelope glycoproteins stabilized in a pretriggered conformation.

Ding H, Nguyen H, Li W, Deshpande A, Zhang S, Jiang F J Virol. 2024; 98(12):e0172024.

PMID: 39508605 PMC: 11650979. DOI: 10.1128/jvi.01720-24.


Stoichiometry of HIV-1 Envelope Glycoprotein Protomers with Changes That Stabilize or Destabilize the Pretriggered Conformation.

Zhang Z, Anang S, Wang Q, Nguyen H, Chen H, Chiu T bioRxiv. 2024; .

PMID: 39484577 PMC: 11527345. DOI: 10.1101/2024.10.25.620268.


Membrane HIV-1 envelope glycoproteins stabilized more strongly in a pretriggered conformation than natural virus Envs.

Zhang Z, Anang S, Nguyen H, Fritschi C, Smith 3rd A, Sodroski J iScience. 2024; 27(7):110141.

PMID: 38979012 PMC: 11228805. DOI: 10.1016/j.isci.2024.110141.


Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.

Ringe R, Colin P, Ozorowski G, Allen J, Yasmeen A, Seabright G PLoS Pathog. 2023; 19(10):e1011601.

PMID: 37903160 PMC: 10635575. DOI: 10.1371/journal.ppat.1011601.


Alterations in gp120 glycans or the gp41 fusion peptide-proximal region modulate the stability of the human immunodeficiency virus (HIV-1) envelope glycoprotein pretriggered conformation.

Zhang Z, Wang Q, Nguyen H, Chen H, Chiu T, Smith Iii A J Virol. 2023; 97(9):e0059223.

PMID: 37696048 PMC: 10537687. DOI: 10.1128/jvi.00592-23.


References
1.
Leaman D, Kinkead H, Zwick M . In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. J Virol. 2010; 84(7):3382-95. PMC: 2838137. DOI: 10.1128/JVI.02363-09. View

2.
Julien J, Lee J, Cupo A, Murin C, Derking R, Hoffenberg S . Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A. 2013; 110(11):4351-6. PMC: 3600498. DOI: 10.1073/pnas.1217537110. View

3.
Liao H, Bonsignori M, Alam S, McLellan J, Tomaras G, Moody M . Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity. 2013; 38(1):176-86. PMC: 3569735. DOI: 10.1016/j.immuni.2012.11.011. View

4.
Pancera M, Shahzad-Ul-Hussan S, Doria-Rose N, McLellan J, Bailer R, Dai K . Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol. 2013; 20(7):804-13. PMC: 4046252. DOI: 10.1038/nsmb.2600. View

5.
Rolland M, Edlefsen P, Larsen B, Tovanabutra S, Sanders-Buell E, Hertz T . Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012; 490(7420):417-20. PMC: 3551291. DOI: 10.1038/nature11519. View